MetLife Investment Management’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-22,869
| Closed | -$134K | – | 2955 |
|
|
2025
Q1 | $134K | Buy |
+22,869
| New | +$120K | ﹤0.01% | 2394 |
|
|
2024
Q4 | – | Sell |
-13,385
| Closed | -$74.8K | – | 2871 |
|
|
2024
Q3 | $74.8K | Sell |
13,385
-7,376
| -36% | -$51.6K | ﹤0.01% | 2706 |
|
|
2024
Q2 | $175K | Buy |
20,761
+1,821
| +10% | +$19.4K | ﹤0.01% | 2334 |
|
|
2024
Q1 | $273K | Hold |
18,940
| – | – | ﹤0.01% | 2013 |
|
|
2023
Q4 | $408K | Hold |
18,940
| – | – | ﹤0.01% | 1810 |
|
|
2023
Q3 | $364K | Hold |
18,940
| – | – | ﹤0.01% | 1825 |
|
|
2023
Q2 | $481K | Hold |
18,940
| – | – | ﹤0.01% | 1712 |
|
|
2023
Q1 | $685K | Hold |
18,940
| – | – | ﹤0.01% | 1449 |
|
|
2022
Q4 | $750K | Hold |
18,940
| – | – | 0.01% | 1373 |
|
|
2022
Q3 | $883K | Hold |
18,940
| – | – | 0.01% | 1258 |
|
|
2022
Q2 | $830K | Hold |
18,940
| – | – | 0.01% | 1312 |
|
|
2022
Q1 | $1.37M | Buy |
18,940
+6,838
| +57% | +$493K | 0.01% | 1157 |
|
|
2021
Q4 | $981K | Hold |
12,102
| – | – | 0.01% | 1135 |
|
|
2021
Q3 | $1.41M | Hold |
12,102
| – | – | 0.01% | 974 |
|
|
2021
Q2 | $2.01M | Sell |
12,102
-668
| -5% | -$104K | 0.02% | 877 |
|
|
2021
Q1 | $1.78M | Sell |
12,770
-689
| -5% | -$112K | 0.02% | 917 |
|
|
2020
Q4 | $2.33M | Sell |
13,459
-608
| -4% | -$98.5K | 0.02% | 749 |
|
|
2020
Q3 | $1.96M | Sell |
14,067
-721
| -5% | -$96.3K | 0.02% | 732 |
|
|
2020
Q2 | $1.77M | Buy |
14,788
+1,758
| +13% | +$209K | 0.02% | 771 |
|
|
2020
Q1 | $1.3M | Hold |
13,030
| – | – | 0.02% | 795 |
|
|
2019
Q4 | $1.53M | Hold |
13,030
| – | – | 0.02% | 911 |
|
|
2019
Q3 | $1.12M | Hold |
13,030
| – | – | 0.01% | 1012 |
|
|
2019
Q2 | $845K | Hold |
13,030
| – | – | 0.01% | 1190 |
|
|
2019
Q1 | $815K | Hold |
13,030
| – | – | 0.01% | 1179 |
|
|
2018
Q4 | $507K | Hold |
13,030
| – | – | 0.01% | 1360 |
|
|
2018
Q3 | $743K | Hold |
13,030
| – | – | 0.01% | 1283 |
|
|
2018
Q2 | $1.04M | Hold |
13,030
| – | – | 0.01% | 1003 |
|
|
2018
Q1 | $1.13M | Hold |
13,030
| – | – | 0.01% | 956 |
|
|
2017
Q4 | $900K | Buy |
+13,030
| New | +$1.04M | 0.01% | 1066 |
|
Other funds holding NVRO
MetLife Investment Management's NVRO Position: Q2 2025 in Review
MetLife Investment Management sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 22,869 shares — an estimated $134K sold.
MetLife Investment Management first reported a position in NVRO in Q4 2017 and held it in 29 quarters. The position peaked at $2.33M in Q4 2020. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- MetLife Investment Management reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- MetLife Investment Management sold 22,869 NEVRO CORP. shares in Q2 2025, an estimated $134K.
- MetLife Investment Management first reported a position in NEVRO CORP. in Q4 2017 and held it in 29 quarters.
- MetLife Investment Management's NEVRO CORP. position peaked at $2.33M in Q4 2020.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.